Intra-Cellular Therapies Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Intra-Cellular Therapies is de winst gegroeid met een gemiddeld jaarlijks percentage van 5.8%, terwijl de Pharmaceuticals industrie de winst daalde met 0.2%. De inkomsten zijn gegroeid met een gemiddelde van 63.9% per jaar.
Belangrijke informatie
5.8%
Groei van de winst
15.8%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 6.0% |
Inkomstengroei | 63.9% |
Rendement op eigen vermogen | -7.5% |
Nettomarge | -14.1% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%
Nov 07Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08Opbrengsten en kosten
Hoe Intra-Cellular Therapies geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 614 | -86 | 471 | 0 |
30 Jun 24 | 565 | -84 | 445 | 0 |
31 Mar 24 | 514 | -111 | 424 | 0 |
31 Dec 23 | 464 | -140 | 410 | 0 |
30 Sep 23 | 420 | -155 | 400 | 0 |
30 Jun 23 | 366 | -184 | 383 | 0 |
31 Mar 23 | 311 | -228 | 382 | 0 |
31 Dec 22 | 250 | -256 | 359 | 0 |
30 Sep 22 | 188 | -298 | 344 | 0 |
30 Jun 22 | 138 | -321 | 326 | 0 |
31 Mar 22 | 103 | -304 | 295 | 0 |
31 Dec 21 | 84 | -284 | 273 | 0 |
30 Sep 21 | 71 | -259 | 251 | 0 |
30 Jun 21 | 56 | -237 | 233 | 0 |
31 Mar 21 | 38 | -232 | 205 | 0 |
31 Dec 20 | 23 | -227 | 186 | 0 |
30 Sep 20 | 10 | -207 | 151 | 0 |
30 Jun 20 | 3 | -187 | 113 | 0 |
31 Mar 20 | 1 | -160 | 87 | 0 |
31 Dec 19 | 0 | -148 | 65 | 0 |
30 Sep 19 | 0 | -148 | 51 | 0 |
30 Jun 19 | 0 | -155 | 44 | 0 |
31 Mar 19 | 0 | -154 | 35 | 0 |
31 Dec 18 | 0 | -155 | 30 | 0 |
30 Sep 18 | 0 | -145 | 27 | 0 |
30 Jun 18 | 0 | -126 | 24 | 0 |
31 Mar 18 | 0 | -106 | 24 | 0 |
31 Dec 17 | 0 | -98 | 24 | 0 |
30 Sep 17 | 0 | -95 | 25 | 0 |
30 Jun 17 | 0 | -102 | 26 | 0 |
31 Mar 17 | 0 | -116 | 26 | 0 |
31 Dec 16 | 0 | -116 | 25 | 0 |
30 Sep 16 | 0 | -118 | 24 | 0 |
30 Jun 16 | 0 | -120 | 22 | 0 |
31 Mar 16 | 0 | -110 | 19 | 0 |
31 Dec 15 | 0 | -105 | 18 | 0 |
30 Sep 15 | 0 | -91 | 15 | 0 |
30 Jun 15 | 0 | -65 | 14 | 0 |
31 Mar 15 | 0 | -48 | 12 | 0 |
31 Dec 14 | 1 | -31 | 10 | 0 |
30 Sep 14 | 1 | -24 | 9 | 0 |
30 Jun 14 | 2 | -22 | 8 | 0 |
31 Mar 14 | 2 | -26 | 7 | 0 |
31 Dec 13 | 3 | -27 | 6 | 0 |
Kwaliteitswinsten: ITCI is momenteel verliesgevend.
Groeiende winstmarge: ITCI is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ITCI is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 5.8% per jaar verminderd.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van ITCI over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: ITCI is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 54.6% ).
Rendement op eigen vermogen
Hoge ROE: ITCI heeft een negatief Return on Equity ( -7.54% ), omdat het momenteel verliesgevend is.